drugset / Trial / NCT00329550
Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active Crohn's disease in the double-blind main study C87037 (NCT00291668).
Timeline
- Start
- 2006-05
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 400 mg | Subcutaneous |